Organon & Co. (OGN)
NYSE: OGN
· Real-Time Price · USD
9.56
-3.37 (-26.06%)
At close: May 01, 2025, 12:11 PM
-26.06% (1D)
| Bid | 9.56 |
| Market Cap | 2.49B |
| Revenue (ttm) | 6.4B |
| Net Income (ttm) | 864M |
| EPS (ttm) | 3.33 |
| PE Ratio (ttm) | 2.87 |
| Forward PE | 3.21 |
| Analyst | Hold |
| Ask | 9.57 |
| Volume | 18,714,527 |
| Avg. Volume (20D) | 3,978,518 |
| Open | 10.18 |
| Previous Close | 12.93 |
| Day's Range | 9.25 - 10.99 |
| 52-Week Range | 9.25 - 23.10 |
| Beta | 0.69 |
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology pr...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 14, 2021
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Website https://www.organon.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20, which is an increase of 109.21% from the latest price.
Stock ForecastsEarnings Surprise
Organon & has released their quartely earnings
on May 1, 2025:
Next Earnings Release
Organon & Co. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 hours ago
Organon shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago
-6.37%
Organon & Co. shares are trading lower after Morgan Stanley and Barclays cut their respective price targets on the stock.
